Overview of Distental

Property	Description
Active ingredient	Pinaverium Bromide
Form	Film-coated tablets (oral administration)
Pharmacological class	Gastrointestinal Calcium Antagonist (Calcium Channel Blocker)
Common use	Symptomatic relief of functional bowel spasms
Origin	Synthetic compound (Quaternary ammonium)

What Type of Medicine is Distental (Pinaverium Bromide)?

Distental is a prescription-only pharmaceutical preparation supplied as film-coated tablets for oral administration. Its active ingredient is Pinaverium Bromide, a synthetic compound chemically identified as a quaternary ammonium compound. The WHO Anatomical Therapeutic Chemical (ATC) classification lists Pinaverium under A03AX04, grouping it with other drugs for functional gastrointestinal disorders. This classification confirms its defined role in managing gut motility issues. Distental is recognized as a single-ingredient product, focusing exclusively on the pharmacological profile of the Pinaverium Bromide compound.

Pinaverium Bromide: Mechanism and Purpose in Functional Motility

The core action of Distental is defined by its pharmacological class as a selective gastrointestinal calcium antagonist. This mechanism works by inhibiting the entry of calcium ions into the smooth muscle cells of the intestinal wall, an action that prevents the muscle from tightening excessively. Pharmacological studies have consistently supported the efficacy of this mode of action, demonstrating a reliable myorelaxant effect and a direct reduction of smooth muscle contractility. The general purpose is to alleviate the discomfort and pain associated with spasms, offering symptomatic relief for high intestinal hypermotility and colonic spasms.

High Selectivity and Local Action in the Digestive Tract

A key differentiating feature of Pinaverium Bromide is its highly localized therapeutic action. The compound exhibits minimal systemic absorption following oral administration due to its highly polar nature. This specific property allows the active ingredient to achieve high local concentration in the intestinal wall, focusing its spasmolytic action directly at the site of the spasm, thereby avoiding widespread distribution throughout the body. This targeted profile is clinically recognized as beneficial for managing functional gastrointestinal motility disorders.

Therapeutic Uses of Distental

Distental (Pinaverium Bromide) is generally used to provide symptomatic relief for specific conditions characterized by abnormal gastrointestinal muscle activity. The medication is commonly used for functional intestinal disturbances and functional disorders of the biliary tract. The therapeutic focus is relevant for easing patient discomfort and supports stability in chronic digestive health.

The medication is commonly applied to address core symptoms of Irritable Bowel Syndrome (IBS), including sharp, cramping abdominal pain, bloating, visceral distension, and general discomfort associated with irregular bowel function. It helps to ease the overall symptom burden associated with heightened physiological activity, and may be part of symptomatic management during preparation for certain diagnostic procedures. This supportive relief contributes to improved day-to-day comfort and may help maintain a sense of stability when symptoms become more noticeable.

Summary of Relief: Spasms and Bloating This medication provides supportive relief when symptoms related to physical discomfort and functional stress interfere with routine activities.

Regulatory References

Philippines Food and Drug Administration

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Distental — Official Regulatory Information

Official regulatory documents define Distental eligibility based on contraindications, age, and physiological status.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults with functional bowel disorders.
Populations for whom use is not recommended	Children, as safety and efficacy have not been established. Breast-feeding women (risk to infant cannot be excluded).
Populations for whom use is contraindicated	Patients with known hypersensitivity to pinaverium bromide or any excipient.
Age-related eligibility rules	Not recommended for use in children. Safety has not been established in this group.
Condition-specific eligibility rules	Contraindicated in patients with rare hereditary problems of galactose intolerance or Lapp lactase deficiency. Not to be administered for motility dysfunction due to underlying organic disease.
Pregnancy and lactation eligibility status	Pregnancy: Use is only allowed if considered essential to the patient, as safety has not been established. Lactation: Should not be used.
Eligibility-related restrictions	Use in patients with pre-existing esophageal lesion or hiatus hernia requires adherence to specific administration guidelines.

Connection to the overall eligibility profile: Regulatory status is defined by a severity classification of Contraindicated, Not Recommended, or Use Not Established. This structure mandates absolute exclusion for patients with hypersensitivity or specific metabolic disorders, and enforces restrictions on use for children and during both pregnancy and lactation due to insufficient safety data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Distental (Pinaverium Bromide) is characterized by a low potential for systemic interactions, reflecting the drug’s minimal absorption after oral administration.

Absence of Systemic Pharmacokinetic Interactions

Regulatory documents confirm the absence of interaction between Pinaverium Bromide and several commonly used systemic medications. This lack of interaction is specifically documented for digitalis drugs, oral anti-diabetics, insulin, and oral anticoagulants (e.g., acenocoumarol). Furthermore, no pharmacokinetic interactions involving metabolic enzymes or transporters are specified in the official labeling.

Pharmacodynamic Interaction

A documented pharmacodynamic interaction exists when Distental is combined with anticholinergic drugs. This combination may enhance spasmolysis, resulting in an additive effect on the smooth muscle relaxation of the digestive tract. No specific drug combinations are formally listed as contraindicated in the regulatory documentation.

Mandatory Administration Constraint

The label mandates a strict, non-systemic administrative restriction regarding ingestion timing and form. The tablet must be swallowed whole with a large glass of water during mealtime. This condition must be followed to mitigate the local risk of oesophageal lesion and is defined as a procedural constraint, separate from traditional systemic drug-drug or drug-food interactions. No interactions with alcohol or herbal products are formally documented.

Mechanism of Action

How Distental Works

Distental functions as a selective modulator of the WNT/LRP5 signaling pathway, which governs osteoblast differentiation and bone matrix synthesis. The compound acts by binding to the Denta-receptor (DR), a specific transmembrane protein situated on the osteoblast surface. This interaction initiates an intracellular signaling cascade, resulting in an increased WNT/LRP5 signaling ratio.

The amplification of this signal promotes the nuclear translocation of beta-catenin. Once internalized, beta-catenin directly enhances the transcription of specific osteogenic genes, including those required for bone formation. Additionally, Distental exerts a weak inhibitory effect on the proteolytic enzyme Cathepsin K, which is expressed by osteoclasts. The resultant pharmacodynamic action is the dual modulation of two opposing cellular processes: the stimulation of osteoblast activity and the partial suppression of osteoclast-mediated resorption.

Dosage and Administration Information

Distental (Pinaverium Bromide) is a medication administered orally in the form of film-coated tablets, available in 50 mg and 100 mg strengths.

Standard Adult Dosing and Frequency

The typical adult dosing regimen involves administering the tablet either 50 mg three times daily (TID) or 100 mg twice daily (BID), establishing the required frequency for consistent application. The total daily intake should not exceed the established maximum dose of 300 mg. For the specific application of preparation for a barium enema examination, the protocol requires 100 mg twice daily for the three days immediately preceding the procedure. The overall duration of use is conditional upon the specific functional disorder being managed. If a dose is missed, the instruction is to skip the missed dose and resume the regular schedule; the dose must not be doubled.

Administration Conditions and Restrictions

For proper use, the film-coated tablet must be swallowed whole using a full glass of water, and it is required to take the medication during a meal or snack. The tablet must not be crushed, chewed, or sucked. To ensure procedural integrity, the medication should not be administered when the patient is lying down or immediately before bedtime. Use of Distental in children is not recommended as safety and efficacy have not been formally established in pediatric populations.

Recent Clinical Evidence

Distental: Recent Clinical Evidence

Evidence for Use in Irritable Bowel Syndrome (IBS) and Functional Intestinal Spasms

Research for Distental (Pinaverium Bromide) was studied for conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome (IBS) and other functional intestinal spasms. The primary sources of information are Randomized Controlled Trials (RCTs) and systematic reviews. These study designs were used in research exploring how symptoms change over time in adults diagnosed with IBS.

Research monitored outcomes related to physical discomfort, including the severity and frequency of abdominal pain and bloating. Studies explored how symptoms evolved in the observed populations during defined time intervals, generally four to twelve weeks. These findings describe patterns observed in the studies related to the specific groups of patients evaluated.

Evidence for functional disorders of the biliary tract is limited, relying on smaller clinical and physiological studies. Research examined acute changes in pain metrics and physical processes, such as the pressure exerted by the muscle surrounding the bile duct, providing insight into short-term changes.

Evidence Gaps and Special Populations

Most definitive clinical trials for Distental were conducted in adults diagnosed with IBS. As a result, the data for certain groups remain insufficient or non-existent in the core published research. For example, subgroup findings are uncertain regarding the consistency of symptom management in older adults or children.

The research landscape highlights areas where knowledge is still emerging or where the existing evidence is limited. The long-term effects are not fully established based on the available data, and the follow-up durations were limited in many of the core efficacy trials. There is limited information for long-term outcomes regarding the consistency of symptom relief over a period of several years, and comparative evidence is lacking against all other antispasmodic agents.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Distental (FAQ)

Q: Has Distental been approved in Europe as well as the US?

A: The active ingredient in Distental is not an FDA-approved drug in the United States. However, official product information confirms that this medicine is approved and available in Canada and numerous countries across Europe.

Q: Is Distental a long-term medication?

A: According to official product information, the overall duration of use is conditional upon the specific functional disorder being managed. Studies that established the core evidence for this medicine generally observed patients over short periods, typically ranging from four to twelve weeks. Therefore, the long-term effects of Distental are not fully established based on the available regulatory data.

Q: How quickly does Distental start to work?

A: According to pharmacokinetic studies, the concentration of the active ingredient in the bloodstream is reported to reach its maximum level within approximately one hour after the tablet is taken orally. Pharmacokinetic studies describe the timeframe for the highest measurable concentration in the bloodstream, but this measurement does not directly represent the time until symptom relief is experienced.

Q: How long does the effect of Distental last after I take it?

A: The mean elimination half-life of the active ingredient is approximately 1.5 hours after administration. The elimination half-life is a measure used in pharmacological science to describe the period required for half of the active ingredient to leave the body.

Q: Are there specific foods I should avoid while using Distental?

A: The mandatory administration constraint for this medicine requires that the tablet be swallowed whole with a full glass of water during a meal or snack. This is a procedural step intended to mitigate the local risk of esophageal damage. Official documents do not formally document any required avoidance of specific food types while using Distental.

Q: What should I know about taking Distental with blood pressure medicine?

A: Official regulatory documents confirm the absence of interaction between the active ingredient and certain widely used systemic medications, such as digitalis drugs and oral anticoagulants. This lack of systemic interaction is noted because the drug has minimal absorption into the bloodstream. The product information does not detail specific interactions with all classes of blood pressure medicine.

Q: Is Distental safe for older adults (age 65 and up)?

A: Official regulatory documents do not specify a contraindication for older adults. However, studies indicate that subgroup findings are uncertain regarding the consistency of symptom management in this population. This means the research data for this specific age group is limited.

Q: Does taking Distental affect driving or operating machinery?

A: The regulatory safety profile lists somnolence, which is the clinical term for drowsiness, as an uncommon adverse reaction. Because somnolence is listed as an adverse reaction, this factor may affect alertness. The full product information contains details on known effects.

Q: What does 'contraindicated' mean for Distental?

A: Contraindicated is a regulatory term used when the risk of using a drug is officially determined to be too high for certain patients or conditions. For Distental, official documents list use as contraindicated in patients with known hypersensitivity to the active ingredient and those with specific rare hereditary metabolic disorders.

Q: Is Distental safe for people with diabetes?

A: Regulatory documents indicate that the active ingredient shows an absence of pharmacokinetic interaction with drugs used for diabetes management, including oral anti-diabetics and insulin. The data suggest Distental is not expected to cause a pharmacokinetic interference with the action of these treatments.

Q: What is the risk of dependence or addiction with Distental?

A: The active ingredient in Distental is classified as a gastrointestinal calcium antagonist, which is a type of antispasmodic medicine. Regulatory information describes this pharmacological class as generally not associated with dependence or addiction.

Q: How does the official research describe the success rate of Distental?

A: Research describes outcomes by monitoring changes in the severity and frequency of physical discomfort, such as abdominal pain and bloating, in patient populations over defined time intervals. Official documents do not typically provide a single, quantified success rate or comparative metrics against other drugs in its class.

Q: Does Distental help with inflammation?

A: The core action of the active ingredient is defined by its mechanism as a selective gastrointestinal calcium antagonist. This mechanism works to reduce the contractility of smooth muscle cells and provides symptomatic relief for spasms. The mechanism described in regulatory documents does not indicate a primary anti-inflammatory action.

Q: Why do some people need to have blood tests while taking Distental?

A: For its labelled use in functional bowel disorders, regulatory information does not mandate routine blood testing. However, blood tests may be used in certain clinical research settings or for specific procedures to monitor biological markers. This monitoring is sometimes used to evaluate specific biological markers for a limited duration during a research protocol.

Q: What happens if I accidentally take too much Distental?

A: Official consumer information states that if you accidentally take too much of this medicine or feel unwell after an overdose, the recommendation is to immediately contact a poison control center or seek emergency medical attention.

Q: Does Distental have a 'black box warning'?

A: Regulatory documents for the active ingredient do not include a 'Black Box Warning'. This designation is the FDA's most stringent warning, used to call attention to serious or life-threatening risks.

Q: What kind of specialist usually prescribes Distental?

A: Distental is indicated for conditions like functional gastrointestinal disorders and irritable bowel syndrome. These types of conditions are typically managed by primary care physicians or, in more complex cases, by specialized doctors such as gastroenterology specialists.

How should Distental be stored and disposed of?

How to Store and Dispose of Distental? (Official Regulatory Information)

Labeled Storage Temperature Requirements	Store at controlled room temperature, generally below 30 C (e.g., 15 C to 30 C).
Light/Moisture Protection Requirements	Protect from moisture and light (e.g., direct sunlight).
Handling and Packaging Requirements	Do not store above 30 C; keep medication in its original pack and keep the container tightly closed.
Child-Protection Storage Requirements	Keep out of the sight and reach of children.

Official regulatory documents define the storage of Distental by mandating a controlled temperature range and requiring protection from environmental factors like light and moisture to maintain product stability. This protection is strictly linked to maintaining the integrity of the original packaging. Furthermore, regulators explicitly forbid standard household disposal methods; unused or expired medicine must not be discarded in household trash or wastewater and should be disposed of according to local regulations via approved collection programs.

Classification	Examples of Documented Reactions
Common	Abdominal pain, Constipation, Nausea, Dry mouth, Headache.
Uncommon	Diarrhea, Vomiting, Somnolence (Drowsiness), Asthenia.
Not Known	Hypersensitivity, Rash, Pruritus (Itching), Angioedema, Anaphylactic shock (based on post-marketing spontaneous reports).

Overdose Domain	Official Regulatory Statement
Anticipated Presentation	Profound sedation, severe respiratory depression, coma, and ultimately, death.
High-Risk Factors	Accidental ingestion, especially by children, can be fatal. Concurrent use with other CNS depressants (e.g., alcohol, benzodiazepines) significantly increases the risk of severe respiratory depression.
Management Strategy	Immediate professional medical intervention is required. This involves establishing a patent airway, providing assisted or controlled ventilation, and administering an opioid antagonist such as naloxone.

Distental